找不到产品?留下需求帮您找
一键询价MKN1 人胃癌细胞 QCH812
一周
3500¥
Phoenix-AMPHO 人肾上皮细胞 QCH813
一周
5500¥
DBTRG-05MG 人脑胶质细胞瘤细胞 QCH814
一周
3500¥
SNU638 人胃癌细胞 QCH815
一周
3500¥
NCI-H2073 人非小细胞肺癌细胞 QCH816
一周
5500¥
HAL01 人急性淋巴细胞白血病细胞 QCH817
一周
2500¥
TMD8 人弥漫性大B细胞淋巴瘤 QCH818
一周
7500¥
SNU484 人胃癌细胞 QCH819
一周
3500¥
JHH2 人肝癌细胞 QCH820
一周
4500¥
LK2 人肺腺癌细胞 QCH821
钦诚生物 | 一周
3500¥
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:UT-155 产品别名:见爱必信官网 英文别名:UT-155 靶点:Androgen Receptor CAS:2031161-35-8 纯度:98% 外观:见爱必信官网 保存方法:store at -20℃ for one year(Powder) 描述:UT-155 is a selective and potent androgen receptor (AR) antagonist, with a Ki of 267 nM for UT-155 binding to AR-LBD. 溶解性: 体外研究: UT-155 binds to the AR-LBD at Ki of 267 nM. UT-155 potently inhibits the R1881-induced wildtype AR transactivation with 6-10-fold higher potency than enzalutamide. While UT-155 antagonizes both wildtype and mutant ARs comparably, enzalutamide is weaker by two fold with the W742L mutant AR relative to the wild type AR. Treatment of LNCaP cells with UT-155 inhibits 0.1 nM R1881-induced PSA and FKBP5 gene expression between 10 and 100 nM with 5-10-fold better potency than enzalutamide. 体内研究:UT-155 binds to the AR-LBD at Ki of 267 nM. UT-155 potently inhibits the R1881-induced wildtype AR transactivation with 6-10-fold higher potency than enzalutamide. While UT-155 antagonizes both wildtype and mutant ARs comparably, enzalutamide is weaker by two fold with the W742L mutant AR relative to the wild type AR. Treatment of LNCaP cells with UT-155 inhibits 0.1 nM R1881-induced PSA and FKBP5 gene expression between 10 and 100 nM with 5-10-fold better potency than enzalutamide.
产品信息订购:
|